IV Golimumab efficacy and Early (ED) vs Late (LD) AS ⭐️ED better response than LD with PRO ⭐️Treatment-emergent adverse events/ serious adverse 🔼 LD as compared to ED Abst #0912 #ACR21 @RheumNow https://t.co/5EaWAvfQ57

French real-world AxSpA cohort analysis showed drug retention of SEC & TNFi were similar. In subgroups analyses, age, BASDAI at dx & BMI were similar. Abs 0911 #ACR21 #RheumNow @RheumNow https://t.co/ewtmpxKTNu https://t.co/Yh0nX3x83Z

• Drug Retention of Tumor Necrosis Factors and IL-17 Inhibitors in Axial Spondylo…

#ACR21 Abst#0836. TCZ switch from IV▶️SC in RA ⭐️11/37 ineffective on SC (30%) ⭐️TCZ IV >8mg/kg, no MTX, h/o ABA failure ass w/ risk of flare on SQ switch 🔥Very relevant w shortages, want more data re: confounders (adherence, disease control) https://t.co/E9pD4SrXqz @Rheumnow

• https://bit.ly/3keDrHK

Getting closer to personalised medicine in AS, ECM-mediated biomarkers may help predict response to Adalimumab in AS. The biomarkers C1M, C6M and PRO-C4 were lower in responders to adalimumab treatment after 24 weeks @RheumNow #ACR21 Abst#0915 https://t.co/K2YxPvUAwu https://t.co/w9kcBSFeG9

• Biomarkers of Extracellular Matrix Turnover Reflect Treatment Response and Phar…

There is increase in ASDAS, BASDAI, CRP and faecal calprotectin levels although not reaching a clinical flare in AS patients who had CZP stopped compared to those who continue CZP full or reduced dose @RheumNow #ACR21 Abst#0916 https://t.co/Wlwirs1QXF https://t.co/jE4smHMXBI

• Disease Activity and Inflammation in Axial Spondyloarthritis Patients Who Did N…

Abst0919 #ACR21 @RheumNow Phase III COAST-V 52W (PBO)-controlled study examined the efficacy of IXE in pts with active AS. SF-36 bodily pain, improvements were observed at W16 & W52 whether inflammation was controlled or not per MRI, CRP, MRI+CRP, or BASDAI 5/6. https://t.co/uHLwFctzPr

Single Intraarticular Canakinumab in Knee OA - 18-week randomized, double-blind, double-dummy Placebo and naproxen-controlled - effect no different than Placebo. Some efficacy in subgroup with high hsCRP. Need for subtypes in OA @rheumnow #ACR21 #abst0728 https://t.co/YlKTMf56wF

@MilenaGianfran @JYazdanyMD present on differential effects of biologics on CDAI in obese patients with rheumatoid arthritis. Abatacept better than TNFi in obese. Tocilizumab better than TNFi in non-obese. Abstr#0588 #ACR21 @RheumNow #ACRBest https://t.co/UcEpMAmNVw

French, real-world axSpA cohort analysis shows SEC and TNFi retention rates similar. What do you see in your practice? Abs 0911 #ACR21 #RheumNow @RheumNow https://t.co/vu3zUwfktl https://t.co/v6DLjWJMn4

• Drug Retention of Tumor Necrosis Factors and IL-17 Inhibitors in Axial Spondylo…